Computational Molecular Biology 2016, Vol.6, No.2, 1-9
8
4 Conclusions
Herein we discussed the differential gene expression analysis of Alzheimer’s disease that mainly expressed in
transcriptional regulation of the cortex of the brain. There are 5527 genes that significantly associated with
differential expression, these genes are further classified according to incipient, moderate, severe and normal
tissues of expression levels shows only More severe condition level has the highest level of gene expression that
significantly expressed in Alzheimer’s disease. Genome wide association of Alzheimer’s disease to predict the
SNPs that transcriptionally associated with the cortex region of brain that regulate protein synthesis. We have
identified 8 biomarkers such as PTN, TBC1D2B, FAR2, LHCGR, EHD1, KCNA5, WDFY3 and ITGBL1 is
mainly involved transcriptional regulation and disease progression. Using Pharmacogenomic analysis of these
genes has good effect for the treatment of AD and is potentially considered to regulate and also to modulate gene
expression but also have important roles in diagnostics.
Acknowledgement
We gratefully acknowledge the assistance of Dr. C. N Prashantha for supporting project work, workflows,
technical assistance and report preparation. We also grateful to Seema J Patel and Anitha P.Muttagi as internal
guide to conduct seminars and guiding project. We also grateful to Department of Biotechnology, GMIT and
Scientific Bio-Minds to providing continuous support to successfully complete the project.
References
Breteler M.M., Claus J.J., van Duijn C.M., Launer L.J., and Hofman A., 1992, Epidemiology of Alzheimer’s disease, Epidemiol. Rev., 14: 59–82.
Bu G., 2009, Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy, Nat Rev Neurosci, 10: 333–344.
Christensen M.A., Zhou W., Qing H., Lehman A., Philipsen S., Song W., 2004, Transcriptional regulation of BACE1, the beta-amyloid precursor protein
beta-secretase by Sp1, Mol Cell Biol, 24(2): 865-74
Cruts M., van Duijn C.M., Backhovens H., Van den Broeck M., Wehnert A., Serneels S., Sherrington R., Hutton M., Hardy J., St George-Hyslop P. H., Hofman
A., and Van Broeckhoven C., 1998, Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile
Alzheimer disease, Hum Mol Genet, 7: 43-51.
Cruchaga C., Haller G., Chakraverty S., Mayo K., Vallania F.L., Mitra R.D., Faber K., Williamson J., Bird T., Diaz-Arrastia R., Foroud, T. M., Boeve B. F.,
Graff-Radford N.R., St Jean P., Lawson M., Ehm M.G., Mayeux R., and Goate A.M., 2012, Rare variants in APP, PSEN1 and PSEN2 increase risk for AD
in late-onset Alzheimer's disease families, PLoS One, 7: e31039.
Citron M., Oltersdorf T., Haass C., McConlogue L., Hung A.Y., Seubert P., Vigo-Pelfrey C., Lieberburg I., and Selkoe D.J., 1992, Mutation of the beta-amyloid
precursor protein in familial Alzheimer's disease increases beta-protein production, Nature 360: 672-674.
Chen J., Li Q., and Wang J., 2011, Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions, Proc Natl Acad Sci USA, 108:
14813–14818.
Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., and Pericak-Vance M.A., 1993, Gene dose
of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families, Science, 261: 921–923.
Di Fede G., Catania M., Morbin M., Rossi G., Suardi S., Mazzoleni G., Merlin M., Giovagnoli A.R., Prioni S., Erbetta A., Falcone C., Gobbi M., Colombo L.,
Bastone A., Beeg M., Manzoni C., Francescucci B., Spagnoli A., Cantu L., Del Favero E., Levy E., Salmona M., and Tagliavini, F., 2009, A recessive
mutation in the APP gene with dominantnegative effect on amyloidogenesis, Science 323: 1473-1477.
De Jonghe C., Esselens C., Kumar-Singh S., Craessaerts K., Serneels S., Checler F., Annaert W., Van Broeckhoven C., and De Strooper B., 2001, Pathogenic
APP mutations near the gamma-secretase cleavage site differentially affect Abeta secretion and APP C-terminal fragment stability, Hum Mol Genet 10:
1665-1671.
Ertekin-Taner N., 2011, Gene expression endophenotypes: a novel approach for gene discovery in Alzheimer's disease, Mol Neurodegener, 6: 31.
Frieden C., and Garai K., 2012, Structural differences between apoE3 and apoE4 may be useful in developing therapeutic agents for Alzheimer's disease, Proc
Natl Acad Sci USA, 109: 8913–8918.
